Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 103,922 |
|
|||||
| News | (3) | ||||||
| Day High | 6.7958 | Low High |
|||||
| Day Low | 6.15 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lantern Pharma Inc | LTRN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.04 | 0.64% | 6.27 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.22 | 6.15 | 6.7958 | 6.27 | 6.23 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 864 | 103,922 | $ 6.44 | $ 668,818 | - | 2.38 - 11.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:57:32 | 1 | $ 6.40 | USD |
Lantern Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 67.71M | 10.87M | - | 0 | -15.96M | -1.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lantern Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LTRN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.11 | 6.7958 | 5.6101 | 6.20 | 83,280 | 0.16 | 2.62% |
| 1 Month | 5.55 | 7.21 | 4.8901 | 5.97 | 118,019 | 0.72 | 12.97% |
| 3 Months | 4.81 | 11.99 | 3.98 | 7.48 | 338,876 | 1.46 | 30.35% |
| 6 Months | 3.99 | 11.99 | 3.51 | 7.00 | 189,030 | 2.28 | 57.14% |
| 1 Year | 5.25 | 11.99 | 2.38 | 6.55 | 114,043 | 1.02 | 19.43% |
| 3 Years | 14.49 | 16.50 | 2.38 | 7.36 | 71,296 | -8.22 | -56.73% |
| 5 Years | 15.16 | 24.84 | 2.38 | 10.08 | 77,036 | -8.89 | -58.64% |
Lantern Pharma Description
| Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. |
